Discover why Johnson & Johnson is a top stock pick for income investors in 2025 with strong sales growth and promising ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to ...

Two attempts by Johnson & Johnson to resolve approximately 60,000 talcum powder lawsuits through bankruptcy courts have ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Johnson & Johnson (JNJ ... world's biggest maker of health care products have depreciated by 7.4% over the course of the past month, underperforming the Medical sector's loss of 7.03% and the ...

The global bone growth products market report includes exclusive data on 30 vendors. The market is highly competitive, with global players like Medtronic, Johnson & Johnson, Stryker, and Zimmer ...